Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
79.50
+2.91 (3.80%)
At close: Feb 24, 2026, 4:00 PM EST
79.50
0.00 (0.00%)
After-hours: Feb 24, 2026, 4:10 PM EST
Inhibrx Biosciences Employees
As of December 31, 2024, Inhibrx Biosciences had 161 total employees, including 156 full-time and 5 part-time employees. The number of employees decreased by 11 or -6.40% compared to the previous year.
Employees
161
Change
-11
Growth
-6.40%
Revenue / Employee
$8,696
Profits / Employee
-$963,267
Market Cap
1.16B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 161 | -11 | -6.40% | 156 | 5 |
| Mar 31, 2024 | 176 | - | - | 170 | 6 |
| Dec 31, 2023 | 172 | - | - | 166 | 6 |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 838 |
| Vir Biotechnology | 408 |
| Pharming Group | 404 |
| Xeris Biopharma Holdings | 394 |
| Geron | 229 |
| Sana Biotechnology | 194 |
| Day One Biopharmaceuticals | 184 |
| ORIC Pharmaceuticals | 106 |
INBX News
- 4 weeks ago - These 20 stocks are strong choices for momentum investors - Market Watch
- 6 weeks ago - Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too - Seeking Alpha
- 2 months ago - Why Inhibrx's Recent Strength May Not Be Built to Last - Benzinga
- 2 months ago - Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program - PRNewsWire
- 3 months ago - Inhibrx Reports Third Quarter 2025 Financial Results - PRNewsWire
- 4 months ago - Inhibrx Announces Participation in Upcoming Scientific Conferences - PRNewsWire
- 4 months ago - Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing - Seeking Alpha
- 4 months ago - Inhibrx shares surge after bone cancer drug slows disease progression in trial - Reuters